Literature DB >> 20417027

Role of MRI in diagnosis and treatment of multiple sclerosis.

Mohammad Ali Sahraian1, Arman Eshaghi.   

Abstract

Magnetic resonance imaging (MRI) has played a unique role in the diagnosis and management of patients with multiple sclerosis (MS). In the recent years, there have been considerable changes in the diagnostic criteria for MS as MR-based studies demonstrated its power in earlier and more accurate diagnosis of the disease. Moreover, MRI metrics have become key supportive outcome measures to evaluate the efficacy of experimental treatments in randomized, controlled trials. MRI can also be used as a prognostic tool in patients with clinically isolated syndrome. Although advanced quantitative MRI measures such as magnetization transfer, spectroscopy, and diffusion imaging have added much more to our knowledge about pathogenesis and natural history of the disease but their cost, availability, complexity and lack of validation have limited their use in routine clinical practice. Conventional MR techniques including proton density, T1/T2-weighted images and fluid-attenuated inversion recovery sequences are now accepted in standard protocols for diagnosis and treatment outcome measures in clinical trials for MS. The present review will focus on the type, morphology and evolution of MS lesions in conventional MRI and discusses their use for the monitoring of the disease both in daily clinical practice and experimental trials.

Entities:  

Mesh:

Year:  2010        PMID: 20417027     DOI: 10.1016/j.clineuro.2010.03.022

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  18 in total

Review 1.  Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis.

Authors:  Morteza Mahmoudi; Mohammad A Sahraian; Mohammad A Shokrgozar; Sophie Laurent
Journal:  ACS Chem Neurosci       Date:  2011-02-04       Impact factor: 4.418

2.  Diffusion fMRI detects white-matter dysfunction in mice with acute optic neuritis.

Authors:  Tsen-Hsuan Lin; William M Spees; Chia-Wen Chiang; Kathryn Trinkaus; Anne H Cross; Sheng-Kwei Song
Journal:  Neurobiol Dis       Date:  2014-03-13       Impact factor: 5.996

Review 3.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

Review 4.  Hyperpolarized carbon-13 magnetic resonance spectroscopic imaging: a clinical tool for studying tumour metabolism.

Authors:  Fulvio Zaccagna; James T Grist; Surrin S Deen; Ramona Woitek; Laura Mt Lechermann; Mary A McLean; Bristi Basu; Ferdia A Gallagher
Journal:  Br J Radiol       Date:  2018-01-19       Impact factor: 3.039

5.  GRAPE: a graphical pipeline environment for image analysis in adaptive magnetic resonance imaging.

Authors:  Refaat E Gabr; Getaneh B Tefera; William J Allen; Amol S Pednekar; Ponnada A Narayana
Journal:  Int J Comput Assist Radiol Surg       Date:  2016-10-28       Impact factor: 2.924

Review 6.  Magnetic Resonance Imaging as a Major Milestone in Multiple Sclerosis Diagnosis and Treatment.

Authors:  Rana Karabudak
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

7.  Local mechanical properties of white matter structures in the human brain.

Authors:  Curtis L Johnson; Matthew D J McGarry; Armen A Gharibans; John B Weaver; Keith D Paulsen; Huan Wang; William C Olivero; Bradley P Sutton; John G Georgiadis
Journal:  Neuroimage       Date:  2013-05-01       Impact factor: 6.556

8.  Translocator protein 18 kDa (TSPO) expression in multiple sclerosis patients.

Authors:  Erin Harberts; Dibyadeep Datta; Selby Chen; Jillian E Wohler; Unsong Oh; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2012-09-06       Impact factor: 4.147

9.  Outcomes-Based Contracting for Disease-Modifying Therapies in Multiple Sclerosis: Necessary Conditions for Paradigm Adoption.

Authors:  Cori Gray; James T Kenney
Journal:  Am Health Drug Benefits       Date:  2019-12

10.  Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis.

Authors:  Melissa M Gresle; Helmut Butzkueven; Gerry Shaw
Journal:  Mult Scler Int       Date:  2011-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.